Hepatocellular carcinoma (HCC) is a primary liver cancer that often occurs in patients with non-viral chronic liver disease (CLD). In order to identify specific pathways that are dysregulated in CLD, researchers compared the gene expression and metabolites of CLD liver tissue from patients with HCC to normal, healthy liver tissue. The study demonstrated that inflammatory and fatty acid oxidation pathways are altered in CLD, providing potential therapeutic targets for HCC prevention.

BUFFALO, NY – April 15, 2025 – A new research paper was published in Oncotarget, Volume 16, on April 4, 2025, titled “Association between two single nucleotide polymorphisms of the Prostaglandin-Endoperoxide Synthase 1 and 2 genes and cell proliferative prostatic diseases in Lebanon.”

Natasha D. Sheybani, PhD, is exploring the potential of focused ultrasound to improve the effectiveness and precision of immunotherapy for breast cancer.

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities are available for the management of HCC, depending on its stage as determined by the Barcelona Clinic Liver Cancer staging system. Because liver transplantation (LT) theoretically removes the cancer and replaces the organ at risk for future malignancy, LT is often considered the most definitive and one of the most efficacious treatment options for HCC. Nevertheless, the success and efficacy of liver transplantation depend on various tumor characteristics. As a result, multiple criteria have been developed to assess the appropriateness of a case of HCC for LT, with the pioneering Milan Criteria established in 1996. Over the past 20 to 30 years, these criteria have been critically evaluated, expanded, and often liberalized to make LT for patients with HCC a more universally applicable option. Furthermore, the development of other treatment modalities has enabled downstaging and bridging strategies for HCC prior to LT. In this narrative and comprehensive review, we provided an update on recent trends in the epidemiology of HCC, selection criteria for LT, implementation of LT across different regions, treatment modalities available as bridges, downstaging strategies, alternatives to LT, and, finally, post-LT surveillance.

A study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), in collaboration with the Instituto de Investigación Biomédica de Barcelona (IRB Barcelona), has identified the most effective subtype of dendritic cell for generating immune memory in response to cancer

Gene sequencing studies have uncovered mutations in key oncogenes responsible for colorectal cancer (CRC) development. CRC tumors exhibit significant heterogeneity, and a subset of tumors harbor other key genetic and epigenetic alterations that drive carcinogenesis. Now, researchers from Japan have characterized gene mutations in CRC tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings highlight alternate site-specific mechanisms of CRC development that can guide treatment selection.

A landmark study has revealed how inherited genetic variants, known as germline variants, play a critical role in the progression of cancer.

The research, conducted by a global consortium of scientists, including Kathleen J. Imbach and contributors from the Josep Carreras Leukaemia Research Institute (IJC), offers new insights into how these genetic factors influence molecular processes across a wide range of cancer types.